296 related articles for article (PubMed ID: 28741117)
1. Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2201-2210. PubMed ID: 28741117
[TBL] [Abstract][Full Text] [Related]
2. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
Zha S; Isaacs WB
Mol Cancer Res; 2005 Feb; 3(2):110-8. PubMed ID: 15755877
[TBL] [Abstract][Full Text] [Related]
3. alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
Kuefer R; Varambally S; Zhou M; Lucas PC; Loeffler M; Wolter H; Mattfeldt T; Hautmann RE; Gschwend JE; Barrette TR; Dunn RL; Chinnaiyan AM; Rubin MA
Am J Pathol; 2002 Sep; 161(3):841-8. PubMed ID: 12213712
[TBL] [Abstract][Full Text] [Related]
4. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Zha S; Ferdinandusse S; Denis S; Wanders RJ; Ewing CM; Luo J; De Marzo AM; Isaacs WB
Cancer Res; 2003 Nov; 63(21):7365-76. PubMed ID: 14612535
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs.
Erdmann K; Kaulke K; Thomae C; Huebner D; Sergon M; Froehner M; Wirth MP; Fuessel S
BMC Cancer; 2014 Feb; 14():82. PubMed ID: 24517338
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of α-methylacyl-CoA racemase is associated with CTNNB1 mutations in hepatocellular carcinomas.
Sekine S; Ogawa R; Ojima H; Kanai Y
Histopathology; 2011 Apr; 58(5):712-9. PubMed ID: 21457159
[TBL] [Abstract][Full Text] [Related]
7. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
8. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
Rubin MA; Zhou M; Dhanasekaran SM; Varambally S; Barrette TR; Sanda MG; Pienta KJ; Ghosh D; Chinnaiyan AM
JAMA; 2002 Apr; 287(13):1662-70. PubMed ID: 11926890
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning and preliminary analysis of the human alpha-methylacyl-CoA racemase promoter.
Chen W; Wu W; Zhao J; Yu C; Liu W; Jiang A; Zhang J
Mol Biol Rep; 2009 Mar; 36(3):423-30. PubMed ID: 18080842
[TBL] [Abstract][Full Text] [Related]
10. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Kunju LP; Chinnaiyan AM; Shah RB
Histopathology; 2005 Dec; 47(6):587-96. PubMed ID: 16324196
[TBL] [Abstract][Full Text] [Related]
11. A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants.
Jiang N; Zhu S; Chen J; Niu Y; Zhou L
PLoS One; 2013; 8(10):e74386. PubMed ID: 24130666
[TBL] [Abstract][Full Text] [Related]
12. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human α-methylacyl CoA racemase (AMACR): a target for prostate cancer.
Carnell AJ; Kirk R; Smith M; McKenna S; Lian LY; Gibson R
ChemMedChem; 2013 Oct; 8(10):1643-7. PubMed ID: 23929631
[TBL] [Abstract][Full Text] [Related]
14. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.
Hsieh IS; Chang KC; Tsai YT; Ke JY; Lu PJ; Lee KH; Yeh SD; Hong TM; Chen YL
Carcinogenesis; 2013 Mar; 34(3):530-8. PubMed ID: 23188675
[TBL] [Abstract][Full Text] [Related]
16. Novel 2-arylthiopropanoyl-CoA inhibitors of α-methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents.
Yevglevskis M; Nathubhai A; Wadda K; Lee GL; Al-Rawi S; Jiao T; Mitchell PJ; James TD; Threadgill MD; Woodman TJ; Lloyd MD
Bioorg Chem; 2019 Nov; 92():103263. PubMed ID: 31536953
[TBL] [Abstract][Full Text] [Related]
17. A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
Jiang Z; Fanger GR; Banner BF; Woda BA; Algate P; Dresser K; Xu J; Reed SG; Rock KL; Chu PG
Cancer Detect Prev; 2003; 27(6):422-6. PubMed ID: 14642549
[TBL] [Abstract][Full Text] [Related]
18. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
Kumar-Sinha C; Shah RB; Laxman B; Tomlins SA; Harwood J; Schmitz W; Conzelmann E; Sanda MG; Wei JT; Rubin MA; Chinnaiyan AM
Am J Pathol; 2004 Mar; 164(3):787-93. PubMed ID: 14982833
[TBL] [Abstract][Full Text] [Related]
19. Trifluoroibuprofen inhibits α-methylacyl coenzyme A racemase (AMACR/P504S), reduces cancer cell proliferation and inhibits in vivo tumor growth in aggressive prostate cancer models.
Festuccia C; Gravina GL; Mancini A; Muzi P; Cesare ED; Kirk R; Smith M; Hughes S; Gibson R; Lian LY; Ricevuto E; Carnell AJ
Anticancer Agents Med Chem; 2014; 14(7):1031-41. PubMed ID: 24712326
[TBL] [Abstract][Full Text] [Related]
20. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M
Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
